Ads
related to: cin 3 vs in situ 1 breast cancer recurrence symptoms treatment guidelines
Search results
Results From The WOW.Com Content Network
Stage 0 is a pre-cancerous or marker condition, either ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS). Stages 1–3 are within the breast or regional lymph nodes. Stage 4 is a metastatic cancer. Metastatic breast cancer has a less favorable prognosis. Receptor status.
Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive cancerous lesion of the breast. [1] [2] DCIS is classified as Stage 0. [3] It rarely produces symptoms or a breast lump that can be felt, typically being detected through screening mammography.
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
Cervical squamous intraepithelial lesion (SIL), previously called cervical intraepithelial neoplasia (CIN), is a form of dysplasia that can progress to cervical cancer. The term carcinoma in situ may be used interchangeably with high-grade SIL. [8] Ductal carcinoma in situ of the breast is the most common precancer in women.
Breast cancer: In breast cancer classification, staging is usually based on TNM, [6] but staging in I–IV may be used as well. Cervical and ovarian cancers: the "FIGO" system has been adopted into the TNM system. For premalignant dysplastic changes, the CIN (cervical intraepithelial neoplasia) grading system is used. [7]
Comedocarcinoma is a kind of breast cancer that demonstrates comedonecrosis, which is the central necrosis [1] of cancer cells within involved ducts. Comedocarcinomas are usually non-infiltrating and intraductal tumors, characterized as a comedo-type, high-grade ductal carcinoma in situ (DCIS).
Ads
related to: cin 3 vs in situ 1 breast cancer recurrence symptoms treatment guidelines